Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.86
ARAY's Cash to Debt is ranked higher than
56% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 4.48 vs. ARAY: 0.86 )
ARAY' s 10-Year Cash to Debt Range
Min: 0.79   Max: No Debt
Current: 0.86

Equity to Asset 0.20
ARAY's Equity to Asset is ranked lower than
56% of the 367 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. ARAY: 0.20 )
ARAY' s 10-Year Equity to Asset Range
Min: -0.65   Max: 0.69
Current: 0.2

-0.65
0.69
F-Score: 4
Z-Score: 0.81
M-Score: -2.80
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -25.53
ARAY's Operating margin (%) is ranked higher than
53% of the 372 Companies
in the Global Medical Devices industry.

( Industry Median: 6.25 vs. ARAY: -25.53 )
ARAY' s 10-Year Operating margin (%) Range
Min: -586.2   Max: 1.28
Current: -25.53

-586.2
1.28
Net-margin (%) -32.67
ARAY's Net-margin (%) is ranked higher than
52% of the 372 Companies
in the Global Medical Devices industry.

( Industry Median: 4.71 vs. ARAY: -32.67 )
ARAY' s 10-Year Net-margin (%) Range
Min: -584.5   Max: 2.56
Current: -32.67

-584.5
2.56
ROE (%) -96.62
ARAY's ROE (%) is ranked lower than
56% of the 368 Companies
in the Global Medical Devices industry.

( Industry Median: 5.93 vs. ARAY: -96.62 )
ARAY' s 10-Year ROE (%) Range
Min: -96.62   Max: 4.12
Current: -96.62

-96.62
4.12
ROA (%) -21.69
ARAY's ROA (%) is ranked higher than
54% of the 382 Companies
in the Global Medical Devices industry.

( Industry Median: 3.43 vs. ARAY: -21.69 )
ARAY' s 10-Year ROA (%) Range
Min: -48.97   Max: 1.82
Current: -21.69

-48.97
1.82
ROC (Joel Greenblatt) (%) -199.58
ARAY's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 13.35 vs. ARAY: -199.58 )
ARAY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -199.58   Max: 13.24
Current: -199.58

-199.58
13.24
Revenue Growth (%) 5.40
ARAY's Revenue Growth (%) is ranked higher than
74% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 5.00 vs. ARAY: 5.40 )
ARAY' s 10-Year Revenue Growth (%) Range
Min: -7   Max: 133.5
Current: 5.4

-7
133.5
» ARAY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

ARAY Guru Trades in Q2 2013

Chuck Royce 1,385,500 sh (+21.38%)
PRIMECAP Management 7,861,600 sh (unchged)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
John Burbank 1,940,013 sh (-51.5%)
» More
Q3 2013

ARAY Guru Trades in Q3 2013

Steven Cohen 650,000 sh (New)
PRIMECAP Management 8,301,600 sh (+5.6%)
Chuck Royce 1,443,500 sh (+4.19%)
John Burbank Sold Out
» More
Q4 2013

ARAY Guru Trades in Q4 2013

Jim Simons 447,523 sh (New)
Steven Cohen 1,007,200 sh (+54.95%)
Chuck Royce 1,468,500 sh (+1.73%)
PRIMECAP Management 8,301,600 sh (unchged)
» More
Q1 2014

ARAY Guru Trades in Q1 2014

Chuck Royce 1,560,000 sh (+6.23%)
PRIMECAP Management 8,785,500 sh (+5.83%)
Steven Cohen 814,200 sh (-19.16%)
Jim Simons 247,640 sh (-44.66%)
» More
» Details

Insider Trades

Latest Guru Trades with ARAY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2013-09-30 Sold Out 0.37%$5.41 - $7.3 $ 8.2330%0
John Burbank 2013-06-30 Reduce -51.5%0.38%$4.17 - $5.9 $ 8.2363%1940013
George Soros 2011-09-30 Sold Out 0.0018%$3.63 - $8.73 $ 8.2340%0
Jean-Marie Eveillard 2011-09-30 Sold Out 0.0011%$3.63 - $8.73 $ 8.2340%0
George Soros 2011-06-30 New Buy$6.72 - $9.49 $ 8.231%16100
Jean-Marie Eveillard 2011-06-30 New Buy$6.72 - $9.49 $ 8.231%28922
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.60
ARAY's P/B is ranked higher than
54% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 3.46 vs. ARAY: 6.60 )
ARAY' s 10-Year P/B Range
Min: 1.1   Max: 11.5
Current: 6.6

1.1
11.5
P/S 1.70
ARAY's P/S is ranked higher than
79% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 3.30 vs. ARAY: 1.70 )
ARAY' s 10-Year P/S Range
Min: 0.81   Max: 5.99
Current: 1.7

0.81
5.99
EV-to-EBIT -24.93
ARAY's EV-to-EBIT is ranked higher than
53% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 44.56 vs. ARAY: -24.93 )
ARAY' s 10-Year EV-to-EBIT Range
Min: 34.1   Max: 802.9
Current: -24.93

34.1
802.9
Current Ratio 2.02
ARAY's Current Ratio is ranked higher than
59% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 2.92 vs. ARAY: 2.02 )
ARAY' s 10-Year Current Ratio Range
Min: 0.92   Max: 3.13
Current: 2.02

0.92
3.13
Quick Ratio 1.48
ARAY's Quick Ratio is ranked higher than
61% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 2.16 vs. ARAY: 1.48 )
ARAY' s 10-Year Quick Ratio Range
Min: 0.72   Max: 2.67
Current: 1.48

0.72
2.67

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 51.40
ARAY's Price/Tangible Book is ranked higher than
51% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 5.99 vs. ARAY: 51.40 )
ARAY' s 10-Year Price/Tangible Book Range
Min: 1.97   Max: 82
Current: 51.4

1.97
82
Price/Median PS Value 1.00
ARAY's Price/Median PS Value is ranked higher than
77% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 1.20 vs. ARAY: 1.00 )
ARAY' s 10-Year Price/Median PS Value Range
Min: 0.48   Max: 3.16
Current: 1

0.48
3.16
Earnings Yield (Greenblatt) 0.50
ARAY's Earnings Yield (Greenblatt) is ranked lower than
59% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 4.90 vs. ARAY: 0.50 )
ARAY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 2.9
Current: 0.5

0.1
2.9
Forward Rate of Return (Yacktman) -2.70
ARAY's Forward Rate of Return (Yacktman) is ranked higher than
68% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 0.97 vs. ARAY: -2.70 )
ARAY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1   Max: 2.1
Current: -2.7

1
2.1

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:XEJ.Germany
Accuray, Inc., was incorporated in California in 1990 and commenced operations in 1992. The Company was reincorporated in 2007 in Delaware. The Company is a radiation oncology company. The Company's technologies are designed specifically to deliver precise radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, and image guided radiation therapy and adaptive radiation therapy tailored to the specific needs of each patient. Its suite of products includes the CyberKnife Systems and the TomoTherapy Systems. The CyberKnife Systems are fully robotic stereotactic radiosurgery systems, or SRS and stereotactic body radiation therapy systems, or SBRT used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimeter accuracy while patients breathe normally. Treatment with the CyberKnife Systems requires no anesthesia, and can be performed in one to five staged treatment sessions on an outpatient basis. In addition, the CyberKnife Systems are designed to minimize many of the risks and complications that are associated with other treatment options. The CyberKnife Systems include: the CyberKnife G4, which includes the Fixed collimator; CyberKnife VSI System, which includes the Fixed and Iris collimators and the new CyberKnife M6 Series System, that comes in configurations that have the option of Fixed collimator, Iris collimator, and a MultiLeaf collimator, or MLC. The TomoTherapy Systems are used to treat a wide range of cancers and tumors, and enable efficient daily imaging to ensure the accuracy of the patient position before each treatment delivery. The TomoTherapy Systems operate on ring gantries and combine integrated CT imaging with intensity modulated radiation therapy or IMRT, which is designed to deliver radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The TomoTherapy Systems include the Hi-Art System, delivering CT-guided, helical IMRT; the TomoHD System, which includes both the TomoHelicalTM and TomoDirectTM treatment modalities and the Tomo H TM Series Systems that come in configuration options of TomoHTM, TomoHD and TomoHDATM and which includes one or more options such as TomoHelicalTM, TomoDirectTM, High Performance VoLo TM Planning and TomoEdge Dynamic Jaws.
» More Articles for ARAY

Headlines

Articles On GuruFocus.com
Accuray: Leading the Field Of Radiosurgery Jul 24 2014 
comment on ARAY May 12 2013 
comment on ARAY May 10 2013 
comment on ARAY May 10 2013 
comment on ARAY May 10 2013 
Weekly CEO Buys Highlight: AGNC, WTSLA, ARAY, FSC, SREV Feb 19 2013 
Weekly CFO Buys Highlight: POL, ARAY, ZBB, CRMD, VRX Dec 19 2011 
Accuray Inc. (ARAY) President & CEO Euan Thomson sells 12,500 Shares Mar 11 2011 
Accuray Inc. (ARAY) SVP COO Chris Raanes sells 1,000 Shares Mar 07 2011 
Accuray Inc. (ARAY) SVP COO Chris Raanes sells 9,000 Shares Mar 02 2011 


More From Other Websites
Luminex Corporation (LMNX) Jumps: Stock Adds 8.1% in Session Jul 30 2014
AngioDynamics Q4 Earnings Beat, Revenues Up on Higher Sales Jul 24 2014
Accuray (ARAY) Jumps: Stock Rises 5.1% Jul 23 2014
Bull of the Day: Accuray (ARAY) Jul 23 2014
Latest MD Buyline Report Shows Highest User Satisfaction Composite Ratings for Accuray Incorporated Jul 17 2014
Latest MD Buyline Report Shows Highest User Satisfaction Composite Ratings for Accuray Incorporated Jul 17 2014
Accuray Shows Continued Improvement Jul 07 2014
Why Accuray (ARAY) Could Beat Earnings Estimates Again Jun 30 2014
ACCURAY INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and... Jun 24 2014
Accuray Incorporated Announces Updated Time of Presentation at Goldman Sachs 35th Annual Healthcare... Jun 09 2014
Can Accuray Incorporated (ARAY) Run Higher on Strong Earnings Estimate Revisions? Jun 02 2014
Accuray Incorporated to Present at Goldman Sachs 35th Annual Healthcare Conference 2014 May 28 2014
Accuray Announces 500th TomoTherapy® System Installation May 22 2014
Hansen Medical (HNSN) in Focus: Stock Rises 5.3% May 21 2014
Accuray Incorporated to Present at 2014 Jefferies Global Healthcare Conference May 19 2014
ACCURAY INC Financials May 16 2014
Why A Short Covering Rally Might Come for Accuray (ARAY) Stock May 15 2014
Accuray Partners with Amerinet, Shares Rise May 14 2014
ACCURAY INC Files SEC form 10-Q, Quarterly Report May 07 2014
Accuray signs new contract with Amerinet May 06 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide